dihydroergotamine has been researched along with nicardipine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Titus, F | 1 |
| Callison, CR; Kumar, AB; Miller, M | 1 |
1 review(s) available for dihydroergotamine and nicardipine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for dihydroergotamine and nicardipine
| Article | Year |
|---|---|
[The treatment of migraine].
Topics: Adrenergic beta-Antagonists; Amitriptyline; Calcium Channel Blockers; Dihydroergotamine; Ergotamine; Flunarizine; Humans; Methysergide; Migraine Disorders; Nicardipine; Nimodipine; Serotonin Antagonists; Serotonin Receptor Agonists; Sumatriptan; Vasoconstrictor Agents | 1997 |
Refractory caffeine and ergot-induced cervico-cerebral vasospasm and stroke treated with combined medical and endovascular approach.
Topics: Adult; Caffeine; Cerebral Angiography; Dihydroergotamine; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Angiography; Migraine Disorders; Nicardipine; Phosphodiesterase Inhibitors; Stents; Stroke; Vasoconstrictor Agents; Vasodilator Agents; Vasospasm, Intracranial | 2012 |